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body mass index (BMI) on survival and the effects of placebo (PBO) and bisoprolol @IS) 
on the development of severe cachexia (definition: weight loss z-6 kg during follow-up) in 
2736 CHF patients I” NYHA III/IV. 
Results: There was a significant decrease in mortality with increasing BMI - for each 1 .O 
unit increase in BMI, the risk of death decreased by 3.5%. Higher BMI predicted better 
survival (pcO.O5), independently of study drug, age, LVEF, NYHA class, and gender (all 
p<O.O5. Patients with BMI >25 kg/m’ had a 25% lower risk to die during follow-up than 
patients with BMI of 25 or less (95% Cl E-39%). Analysing 4 BMI categories, PBO and 
BIS total mortality during follow-up was as follows: BMI ~22 kg/m* 23.1 vs 16.5%; BMI 
22 to ~25 kg/m’ - 21.5 vs 10.3%; BMI 25 to ~30 kg/m* - 15.6 vs 12.5%; and BMI ?30 kg/ 
m* - ll.Evs9.3%. 
During follow-up, 110 (8.6%) BIS patients and 148 (11.4%) PBO patients developed 
severe cachexia (hazard ratio for BIS: 0.72. 95%CI 0.56-0.91, ~~0.02) [at 12 months: 5.7 
vs 7.6%. pcO.O5]. BIS (but not PBO) patients showed a significant increase in body 
weight, which was not related to fluid retention. Excluding patients with peripheral 
edema, mean changes in weight in the BIS and PBO groups were +0.2 vs -0.2 kg 
(p=O.OOlE) after 15 weeks, +0.8 vs -0.04 kg (pcO.0001) after 12 months, and +I.2 vs 
+0.03 kg (p=O.O041) after 24 months of maintenance therapy. 
Conclusion: In severe CHF, bisoprolol increases body weight and reduces the inci- 
dence of new cachexia. Given the association of body mass and survival, prevention and 
reversal of cachexia may contribute to the benefits of bisoprolol in patients with CHF. 
1061-73 The Relationship Between Body Weight and Mortality in 
Patients With Decompensated Heart Failure 
Doron Aronson, Darlene P. Horton, Andrew J. Burger, Rambam Medical Center, Haifa, 
Israel, Beth Israel Deaconess Medical Center, Boston, MA 
Introduction: Obesity is generally regarded as an aggravating factor in patients with 
head failure (HF). However, recent studies suggest that increased body mass index may 
be an independent predictor of improved surwal in patients with advanced HF (J Am 
Coil Cardiol 2001;38:789). 
Methods: We studied 560 patients (age 63 * 14 years [range 20 to 931) with a pretiious 
diagnosis of HF (96% with NYHA functional class Ill or IV) who were admitted for decom- 
pensated heart failure. The patients were divided into 2 groups based on median body 
weight (78 Kg). 
Results: During a mean follow-up of 343 * 185 days, 177 patients (32%) died. Kaplan- 
Meier analysis showed that patients wth body weight above the group median were at a 
lower risk of death (Fiaure). In a Cox Droportional-hazards model, adiusted for aae. oen- _ _ _ 
der, diabetes, primary etiology of HF stratified as ischemlc or nonischemic, serum 
sodium. creatinine. and medications (ACE inhibitors. O-blockers. diaoxin. or amio- 
1  
darone), body weight above group median was an independent predictor of improved 
survival after hospital discharge (RR = 0.68, 95% Cl 0.49-0.95. p = 0.022). Predictors of 
increased mortality included age > 65 (RR = 1.6, 95% Cl 1.2-2.2, p = 0.004), sodium < 
135 mmol/L (RR = 1.9, 95% Cl 1.4-2.6, p = O.OOOl), and ischemic HF (RR = 1.7,95% Cl 
1.3-2.4. p = 0.006). 
Conclusion: In patients with advanced heart failure admitted for heart failure decompen- 
sation. increased body weight is an independent predictor of improved survival after hos- 
pital discharge. 
Log Rank P= 0.024 
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1061-74 The Activation of the NF-KB System in Chronic Heart 
Failure 
Ewa A. Jankowska, Anna Czamy. Ewa zaczynska. Waldemar Banasiak, Stefan D. 
Anker. Piotr Ponikowski, Military Hospital, Wroclaw. Poland, Institute of Immunology and 
Experimental Therapy, Wroclaw, Poland 
Background: Inflammatory immune activation is important in the pathogenesis of CHF 
(chronic heart failure). The endotoxin hypothesis suggests that LPS (lipopolisaccharide) 
is an important trigger for cytokine production in CHF. In this context transcriptional factor 
NF-& may be important as a regulator of the response to LPS. In CHF the activabon of 
NF-ti system in immunocompetent cells has not been reported yet. Peripheral blood 
leukocytes (PBL) participate directly in the body’s immune response (to LPS), and were 
the target of our analyses. Methods: We studied 43 CHF pts (62*2y. 77% men, LVEF 
3lil%. 84% with CAD,_NYHA l/II/Ill/IV - 4/16/18/5), 11 CAD pts wthout CHF (62+3y, 
73% men, LVEF 57*4%) and 14 healthy subjects (32+4y, 57% men). The immunohis- 
tochemical localization and protein expression of NFxB in PBL were assessed using 
anti-c-Rel-antibody (PBL expressing c-Rel in the nucleus = labelled NF-rB(+)cells). The 
NF-KB activation in PBL was expressed as 1) the percentage of NF-&(+)cells and 2) the 
ratio of NF&(+)cells to NF-rB(-)cells. Results: NF-KB activation was greatest in CHF 
compared to CAD pts (pcO.05) and healthy subjects (p-zO.01) (NF&(+)cells: 36.2il.5 % 
vs. 29.1e3.0 % vs. 12.6tl.4 %; NFxB(+)cells/NF-+B(-)cells: 0.60*0.04 vs. 0.44+0.06 vs. 
0.15*0.02, respectively). After LPS stimulation the pattern of PBL c-Rel staining was sim- 
ilar in CHF pts and healthy subjects. In PBL from healthy subjects. the LPS stimulation (5 
W/ml for 24h) resulted in translocation of c-Rel into the nucleus (13.8+1.8 % to 42.&i .7 
%, pcO.001). In CHF pts with peripheral edema, NF-ti activation was greater than in 
those without edema (~~0.05) (NF&(+)call~: 39.9i2.4 % vs. 34.2il.8 %; NF- 
xB(+)cellsfNF-a(-)cells: 0.7liO.08 vs. 0.55iO.04). There were no relationships between 
age, LVEF, CHF etiology and NYHA class vs. the NF-KB activation in CHF pts (all 
~~0.2). Conclusions: This study demonstrates the activation of NF-163 system in PBL in 
CHF patients. Therapies that inhibit signal transduction may be useful as anti-inflamma- 
toty therapies in patients with decompensated CHF. 
1061-75 Anemia in Ambulatory Patients With Chronic Heart 
Failure: A Single-Center Clinical Experience Derived 
From Electronic Medical Records 
W.H. Wilson Tanq, Holly Miller, Mary Partin. C. Martin Harris, James B. Young, The 
Cleveland Clinic Foundation, Cleveland, OH 
Background: Patterns of diagnosis and workup of anemia in the contemporary outpa- 
tient management of chronic heart failure is unknown. 
Methods We reviewed 2,011 consecutive ambulatory patients with chronic stable heart 
failure seen at tertiary care cardiology (CV) or internal medicine (IM) clinics between 101 
99-5/02. Anemia was defined as hemoglobin = 12.0 g/dL (men) or = 11 g/dL (women). 
Patients were excluded if anemia was caused by a documented history of active bleeding 
or cancer. Clinical, demographic, laboratory data, and ICD-9 coding data were extracted 
from electronic medical records (EpiCare. Epic Systems Co.) and compared using 
uwariate analyses. Results: In this study cohort (mean age 62+14 years, 64% male, 
73% Caucasian), the mean hemoglobin level was 14 il.8 g/dL in men and 13 +I .6 g/dL 
in women. The prevalence of anemia at the initial patient evaluation was 16.1% (17.3% 
in men, 14.0% in women, n=2,01 I). Microcytic (MCV < 82 fl) and macrocytic (MCV > 98 
fl) anemia were found in 24.5% and 4.3% of patients respectively, with more microcytic 
anemia in women (29.4% vs 22.2%). Diagnostic evaluation for anemia was performed in 
6% of all patlents, and 10% received medlcal therapy for anemia. With a mean follow-up 
of 14.3 months, new-onset anemia developed in 17.5% of patients (19.2% in men, 14.7% 
in women). In addition, 6.6% of anemic patients normalized their hemoglobin levels upon 
repeat evaluattons @=I ,593). Within the 3.5.years of follow-up, 29% of patients devel- 
oped anemia at some point. Although patients seen in IM clinics (n=405) were older, 
were more often women. and had similar anemia profiles, more diagnoses of anemia by 
ICD-9 coding were recognized in the IM clinics versus in the CV clinics (11 .I% vs 4.4%, 
n=l,606). Conclusion: Anemia in ambulatory patients with chronic heart failure is under- 
recognized, under-diagnosed, and under-treated. Utilizing electromc medical records to 
extract pertinent data, the ‘“real-world” epidemiology of the dual diagnoses of anemia and 
head failure can be characterized. 
1061-76 Uncoupling of eNOS in Congestive Heart Failure 
David R. Moraaq Lana J. Dixon, Naglaa A. El-Sherbeeny, Sinead M. Hughes, Lawrence 
T. McGrath, William J. Leahey. Adrian Devine, G. Dennis Johnston, Gary E. McVeigh, 
Queen’s University Belfast, Belfast, United Klngdom 
Background: Endothelium-dependent vasodilation is abnormal in congestive heart fail- 
ure (CHF). Endothelium-dependent regulation of vascular tone is mediated by endothe- 
lium derived nitric oxide (NO). In CHF enhanced basal NO production has been noted. 
Decreased NO bioavailability may, however, be present due to increased biodegradation 
of NO by increased levels of superoxide anion (02.). In nitrate tolerance and diabetes 
endothelial nitric oxide synthase (eNOS) can itself be uncoupled and produce 02.. We 
hypothesised that platelet eNOS can generate 02. in patients with CHF resulting in 
diminished forearm blood flow (FABF) responses to endothelium-dependent vasodila- 
tars. Methods: 18 CHF and 15 aged matched controls were recruited. Isolated platelets 
were collected and prepared by centrifugation and gel filtration. Released 02-was mea- 
sured by enhanced chemiluminescence detection using lucigenin in the presence and 
absence of I\B-Nitro-L-arginine methyl ester (L-NAME). FABF responses were measured 
by venous occlusion plethysmography before and after intra-arterial infusion of acetyl- 
choline (ACH). 
Results: Superoxide release in the absence of L-NAME was lower in controls than 
patients (I .23+0.10 versus 101.6+73.3 pmoles/minll~ platelets, pcO.01). Incorporation 
of L-NAME into the sample increased 02. in both controls and 9 patients (group A) by 
63i9% (pcO.001) and 101*24% (p<O.OOl) respectively. In 9 of the patients (group B) 
02- production decreased in the presence of L-NAME (-39+7%, ~~0.05). Following ACH 
infusion there was an increase in FABF in all groups. There was a significant reduction in 
area under curve (AUC) response in patient group B compared with group A and a fur- 
ther redsuction compared with controls (5.15k6.9 vs 13.8k7.7 vs 24.4kl5.2. pcO.02). 
Conclusion:These data supporl the hypothesis that eNOS can be uncoupled and gen- 
erate 02-. In addition group B there was a significantly Impaired response to ACH dem- 
onstrating that eNOS uncoupling has implications for vascular reactivity. This IS the first 
study showing that eNOS can be uncoupled in CHF in humans producing 02- and con- 
tributing to peripheral vasoconstriction. 
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